Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVM-022 Gene Therapy in Wet AMD
NCT03748784Phase 1Completed
- Sponsor
- Adverum Biotechnologies
- Start
- Nov 2018
- Primary completion
- Jun 2022
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 1, open-label trial of ixoberogene soroparvovec in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Adverum Biotechnologies. Primary endpoint: Type, severity, and incidence of ocular and systemic adverse events at 104 weeks. Started Nov 2018; status: completed.
02
Drugs
ixoberogene soroparvovec
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03748784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03748784.